Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Baxter
McKinsey
McKesson
Citi
Novartis
US Army
Argus Health
Queensland Health
Express Scripts

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,172,107

« Back to Dashboard

Which drugs does patent 6,172,107 protect, and when does it expire?

Patent 6,172,107 protects MYFORTIC and is included in one NDA.

This patent has fifty-seven patent family members in thirty-eight countries.
Summary for Patent: 6,172,107
Title: Entric-coated pharmaceutical compositions
Abstract:This invention provides a pharmaceutical composition comprising a mycophenolate salt, the composition being adapted to release mycophenolate in the upper part of the intestinal tract.
Inventor(s): Haeberlin; Barbara (Riehen, CH), Mak; Ching-Pong (Therwil, CH), Meinzer; Armin (Buggingen, DE), Vonderscher; Jacky (Riedisheim, FR)
Assignee: Novartis AG (Basel, CH)
Application Number:09/469,536
Patent Claim Types:
see list of patent claims
Composition; Use;

Drugs Protected by US Patent 6,172,107

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis MYFORTIC mycophenolic acid TABLET, DELAYED RELEASE;ORAL 050791-001 Feb 27, 2004 AB RX Yes No ➤ Subscribe ➤ Subscribe Y PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS RECEIVING ALLOGENEIC RENAL TRANSPLANTS ➤ Subscribe
Novartis MYFORTIC mycophenolic acid TABLET, DELAYED RELEASE;ORAL 050791-002 Feb 27, 2004 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS RECEIVING ALLOGENEIC RENAL TRANSPLANTS ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,172,107

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9607564Apr 12, 1996
United Kingdom9622028Oct 24, 1996

Non-Orange Book US Patents Family Members for Patent 6,172,107

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,025,391 Enteric-coated pharmaceutical compositions of mycophenolate ➤ Subscribe
6,306,900 Enteric coated pharmaceutical compositions ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,172,107

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2250906 ➤ Subscribe
Indonesia 18663 ➤ Subscribe
European Patent Office 1221316 ➤ Subscribe
Spain 2178510 ➤ Subscribe
Spain 2216141 ➤ Subscribe
France 2747920 ➤ Subscribe
United Kingdom 9821304 ➤ Subscribe
Hungary 224919 ➤ Subscribe
Hungary 9903373 ➤ Subscribe
Hong Kong 1016490 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Citi
Mallinckrodt
Chubb
Farmers Insurance
Healthtrust
Queensland Health
Teva
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot